KR920019352A - 리노바이러스(Rhinoviruses)에 의한 감염 치료에 적합한 합성 화합물 - Google Patents
리노바이러스(Rhinoviruses)에 의한 감염 치료에 적합한 합성 화합물 Download PDFInfo
- Publication number
- KR920019352A KR920019352A KR1019920006514A KR920006514A KR920019352A KR 920019352 A KR920019352 A KR 920019352A KR 1019920006514 A KR1019920006514 A KR 1019920006514A KR 920006514 A KR920006514 A KR 920006514A KR 920019352 A KR920019352 A KR 920019352A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- formula
- rhinoviruses
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 리노바이러스에 의한 감염 치료에 적합한 약제 제조를 위한 일반식(Ⅰ)화합물.상기식에서 R은 치환체(예 : 할로겐, 알킬 또는 프로밀)를 함유하거나 함유하지 않은, 포화되거나 불포화된 5-또는 6-원자 헤테로사이클릭 라디칼, 사이클로알킬이고, X는 H2, O, N-O-R2(여기에서 R2는 H, 알킬이다)이며, n은 3내지 7의 정수이고,〔여기에서, Y, Z, W, K는 H는 H, 할로겐, NO2, CH3, CF3, CHO, O-알킬, -CH=CH2이며, A는 COOR3(여기에서 R3는 H, 알킬이다).(여기에서 Q는 H, 알킬이다).이다〕이다,
- 제1항에 있어서, R이 피롤, 피롤리딘, 푸란, 티오펜, 이미다졸, 피라졸, 피페라진 라디칼이며, 알킬이 알킬 C1-C6-라디칼인 화합물.
- 제1항에 있어서, 하기 구조식을 갖는 화합물.
- 제1항에 있어서, 하기 구조식을 갖는 화합물.
- 제1항에 있어서, 하기 구조식을 갖는 화합물.
- 제1항에 있어서, 하기 구조식을 갖는 화합물.
- 제1항에 있어서, 하기 구조식을 갖는 화합물.
- 약리학적으로 활성인 양의 제1항에 따른 일반식(Ⅰ)의 화합물 및 약리학적으로 허용가능한 희석제 및 부형제를 포함하는 리노바이러스에 의한 감염 치료에 적합한 약제 조성물.
- 환류조건하에 요오화나트륨 및 무수 탄산칼륨 존재하에, 아세토니트릴중에서 일반식(Ⅱ)의 화합물과 구조식(Ⅲ)′,(Ⅲ)″또는 (Ⅲ)″의 화합물을 1 : 1.2 내지 1 : 0.8의 몰비로 반응시킴을 특징으로 하여, 일반식(Ⅰ)의 화합물을 제조하는 방법.상기식에서, R은R1은X는 H2또는 0, 이고, n은 3 내지 7의 정수이다.
- 리노바이러스에 의한 감염의 치료에 적합한 약제조성물을 제조하기 위한 제1항에 따른 일반식(Ⅰ)의 화합물의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI911096A IT1247509B (it) | 1991-04-19 | 1991-04-19 | Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus |
ITMI91A001096 | 1991-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920019352A true KR920019352A (ko) | 1992-11-19 |
Family
ID=11359712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920006514A KR920019352A (ko) | 1991-04-19 | 1992-04-18 | 리노바이러스(Rhinoviruses)에 의한 감염 치료에 적합한 합성 화합물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5278184A (ko) |
EP (1) | EP0509469A1 (ko) |
JP (1) | JPH05148226A (ko) |
KR (1) | KR920019352A (ko) |
CA (1) | CA2066394A1 (ko) |
IT (1) | IT1247509B (ko) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1231212C (zh) | 1999-01-22 | 2005-12-14 | 依兰制药公司 | 抑制vla-4介导的白细胞粘着的多环化合物 |
ES2339738T3 (es) | 1999-01-22 | 2010-05-25 | Elan Pharmaceuticals, Inc. | Derivados de acilo los cuales tratan trastornos relacionados con vla-4. |
CA2359112A1 (en) * | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
CA2361162A1 (en) | 1999-03-01 | 2000-09-08 | Elan Pharmaceuticals, Inc. | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists |
US6428942B1 (en) * | 1999-10-28 | 2002-08-06 | Fujitsu Limited | Multilayer circuit structure build up method |
CN1329390C (zh) | 2000-02-15 | 2007-08-01 | 苏根公司 | 吡咯取代的2-二氢吲哚酮蛋白激酶抑制剂 |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
US6642232B2 (en) | 2001-10-10 | 2003-11-04 | Sugen, Inc. | 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors |
TW200307671A (en) * | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
TWI281470B (en) * | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
NZ567270A (en) * | 2005-09-29 | 2011-06-30 | Elan Pharm Inc | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
CA2851103A1 (en) * | 2005-09-29 | 2007-04-12 | Elan Pharmaceuticals, Inc. | Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4 |
KR20080100271A (ko) * | 2006-02-27 | 2008-11-14 | 엘란 파마슈티칼스, 인크. | Vla-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물 |
EP2424841A1 (en) * | 2009-04-27 | 2012-03-07 | Elan Pharmaceuticals Inc. | Pyridinone antagonists of alpha-4 integrins |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4205078A (en) * | 1977-08-03 | 1980-05-27 | Warner-Lambert Company | 3-Pyrrolin-2-one derivatives |
CA1299176C (en) * | 1985-07-02 | 1992-04-21 | Guy Dominic Diana | Process for preparing isoxazole and furan derivatives |
ZA846525B (en) * | 1983-08-29 | 1985-04-24 | Sterling Drug Inc | (substituted)phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof |
NZ209209A (en) * | 1983-08-29 | 1988-02-12 | Sterling Drug Inc | Substituted phenyl-aliphatic isoxazole derivatives and pharmaceutical compositions |
US4861791A (en) * | 1983-08-29 | 1989-08-29 | Sterling Drug Inc. | Dihydro-oxazolyl substituted-phenyl-aliphatic lower alkyl and their use as antiviral agents |
DE3825559A1 (de) * | 1988-07-28 | 1990-02-01 | Basf Ag | P-hydroxiphenon-derivate und deren anwendung |
GB8912303D0 (en) * | 1989-05-27 | 1989-07-12 | Pfizer Ltd | Therapeutic agents |
US5100893A (en) * | 1990-04-18 | 1992-03-31 | Janssen Pharmaceutica N.V. | Antipicornaviral pyridazinamines |
DE4020851A1 (de) * | 1990-06-29 | 1992-01-02 | Cassella Ag | 2-(aminoalkyl)-pyrrolaldehyde, verfahren zu ihrer herstellung und ihre verwendung |
-
1991
- 1991-04-19 IT ITMI911096A patent/IT1247509B/it active IP Right Grant
-
1992
- 1992-04-15 EP EP92106481A patent/EP0509469A1/en not_active Withdrawn
- 1992-04-16 CA CA002066394A patent/CA2066394A1/en not_active Abandoned
- 1992-04-17 US US07/870,625 patent/US5278184A/en not_active Expired - Fee Related
- 1992-04-18 KR KR1019920006514A patent/KR920019352A/ko not_active Application Discontinuation
- 1992-04-20 JP JP4128324A patent/JPH05148226A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH05148226A (ja) | 1993-06-15 |
US5278184A (en) | 1994-01-11 |
ITMI911096A1 (it) | 1992-10-19 |
ITMI911096A0 (it) | 1991-04-19 |
CA2066394A1 (en) | 1992-10-20 |
IT1247509B (it) | 1994-12-17 |
EP0509469A1 (en) | 1992-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920019352A (ko) | 리노바이러스(Rhinoviruses)에 의한 감염 치료에 적합한 합성 화합물 | |
KR960704884A (ko) | 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents) | |
DE3367774D1 (de) | 5,6,7-trinor-4, 8-inter-m-phenylene prostaglandin i2 derivatives | |
RU93048539A (ru) | Производные оксазолидина, обладающие противодиабетическими свойствами и действием против ожирения, их получение и терапевтическое применение | |
ATE131165T1 (de) | Leukotrien-b4-antagonisten. | |
OA07151A (fr) | Dérivés de la pyrrolidine . | |
KR960007592A (ko) | 신규한 피롤로카바졸 | |
FR2403333A1 (fr) | Analogues de la prostaglandine e1 et compositions pharmaceutiques les contenant | |
KR900016098A (ko) | 카페인산의 유도체 및 이를 함유하는 약제학적 조성물 | |
KR920017669A (ko) | 갈륨 화합물 | |
KR860008973A (ko) | 2-피롤리돈 유도체 | |
AU572690B2 (en) | Tricyclic or tetracyclic compounds, process for their preparation, and medicinal composition containing them | |
KR900001715A (ko) | Bu-3608 유도체 | |
KR880003941A (ko) | 4,5-디하이드로옥사졸 유도체, 그의 제조방법 및 용도 | |
ES438314A1 (es) | Un procedimiento para preparar los compuestos de decahi- droisoquinolina. | |
KR940007001A (ko) | 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제 | |
KR920002517A (ko) | 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법 | |
KR940005638A (ko) | 티에노티아진 유도체, 이의 제조방법 및 용도 | |
KR890002111A (ko) | 벤즈이미다졸 유도체, 그의 제법 및 치료에의 이용 | |
SE8302045L (sv) | Furanderivat | |
DK0411394T3 (da) | Imidazoquinolon-derivater | |
BR9006025A (pt) | Preparacao farmaceutica | |
KR890007741A (ko) | 진통제 | |
SE7412163L (ko) | ||
SE8301785L (sv) | Sett att framstella 2-tiofen-ettiksyraderivat och mellanprodukter erforderliga for deras framstellning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |